Marinus Pharmaceuticals Inc (MRNS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Christopher Michael Cashman
Employees:
28
170 N RADNOR CHESTER RD, SUITE 250, RADNOR, PA 19087
484-801-4670

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of neuropsychiatric therapeutics. Its clinical stage drug candidate, ganaxolone, is a novel synthetic small molecule that is an analog of allopregnanolone, a natural occurring neurosteriod produced by the human body, which modulates gamma-aminobutyric acid a neurotransmitter in the brain. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Data derived from most recent annual or quarterly report
Market Cap 203.149 Million Shares Outstanding37.003 Million Avg 30-day Volume 239.881 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.29
Price to Revenue28.3845 Debt to Equity0.763 EBITDA-95.37 Million
Price to Book Value8.8557 Operating Margin-631.6781 Enterprise Value357.744 Million
Current Ratio3.246 EPS Growth0.039 Quick Ratio3.095
1 Yr BETA 1.7459 52-week High/Low 19.83 / 4.19 Profit Margin-643.7015
Operating Cash Flow Growth8.9227 Altman Z-Score-2.4772 Free Cash Flow to Firm -42.004 Million
View SEC Filings from MRNS instead.

View recent insider trading info

Funds Holding MRNS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MRNS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DOUGHERTY MICHAEL R

  • Director
15,687 2022-02-04 1

VITULLO NICOLE

  • Director
18,817 2022-02-04 1

MANNING MARTHA E VP GEN COUNSEL AND CORP SEC.

  • Officer
70,767 2022-02-04 1

MAYLEBEN TIMOTHY M

  • Director
26,250 2022-02-04 1

EZICKSON ELAN

  • Director
15,125 2022-02-04 1

FISCHER SETH H. Z.

  • Director
15,819 2022-02-04 1

BRAUNSTEIN SCOTT CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
260,950 2022-02-04 1

ARROYO SANTIAGO

  • Director
15,125 2022-02-04 3

HULIHAN JOSEPH CHIEF MEDICAL OFFICER

  • Officer
94,325 2022-02-04 1

AUSTIN CHARLES

  • Director
15,125 2022-02-04 1

NOCHUR SARA

  • Director
15,125 2022-02-04 1

PFANSTIEL STEVEN CHIEF FINANCIAL OFFICER

  • Officer
91,025 2022-02-04 1

SMITH EDWARD F FORMER VP, CFO & TREASURER

  • Officer
No longer subject to file 2021-03-09 0

CARRAZANA ENRIQUE J.

  • Director
0 2021-01-15 0

LORIANNE MASUOKA K. CHIEF MEDICAL OFFICER

  • Officer
0 2019-08-21 0

CASHMAN CHRISTOPHER MICHAEL CEO

  • Officer
  • Director
No longer subject to file 2019-03-18 0

BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC

BAIN CAPITAL LIFE SCIENCES PARTNERS, LP

BAIN CAPITAL LIFE SCIENCES FUND, L.P.

BCIP LIFE SCIENCES ASSOCIATES, LP

SCHWARTZ JEFFREY LAWRENCE

KOPPEL ADAM

  • 10% Owner
No longer subject to file 2017-12-15 0

SHEPARD JAY

  • Director
0 2017-01-17 0

MEHRA ANAND

SOFINNOVA VENTURE PARTNERS VI L P

SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

SOFINNOVA VENTURE AFFILIATES VI LP

SOFINNOVA MANAGEMENT VI, L.L.C.

BUATOIS ERIC

HEALY JAMES

AZAN ALAIN

POWELL MICHAEL

  • 10% Owner
No longer subject to file 2016-10-20 0

CANAAN VII LP

CANAAN PARTNERS VII LLC

  • 10% Owner
No longer subject to file 2016-08-05 0

MEHRA ANAND

  • Director
0 2016-08-03 0

PATRONEVA ALBENA CHIEF MEDICAL OFFICER

  • Officer
0 2016-08-03 0

BLOCH STEPHEN M

  • Director
2,500,948 2015-09-24 0

FARFEL GAIL M CHIEF CLINICAL DEV & REG OFFIC

  • Officer
0 2015-04-21 0

SHAH NIMESH

  • 10% Owner
42,550 2015-01-01 0

GOPKA ANTON

  • Director
0 2014-09-30 0

DOMAIN PARTNERS VI, L.P.

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

SCHOEMAKER KATHLEEN K

VITULLO NICOLE

  • Director
  • 10% Owner
2,476,886 2014-08-05 0

DP VI ASSOCIATES, L.P.

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

SCHOEMAKER KATHLEEN K

VITULLO NICOLE

  • Director
  • 10% Owner
17,000 2014-08-05 0

DOMAIN ASSOCIATES

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

SCHOEMAKER KATHLEEN K

VITULLO NICOLE

HALAK BRIAN K

KAMDAR KIM P.

  • Director
  • 10% Owner
42,550 2014-07-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 22:15:04 UTC -0.2321 1.0521 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 21:45:04 UTC -0.229 1.049 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 21:15:03 UTC -0.229 1.049 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 20:45:03 UTC -0.2085 1.0285 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 20:15:05 UTC -0.2085 1.0285 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 19:45:04 UTC -0.2085 1.0285 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 19:15:03 UTC -0.2085 1.0285 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 18:45:03 UTC -0.195 1.015 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 18:15:03 UTC -0.195 1.015 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 17:45:03 UTC -0.195 1.015 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 17:15:03 UTC -0.195 1.015 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 16:45:04 UTC 0.0304 0.7896 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 16:15:03 UTC 0.0304 0.7896 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 15:45:03 UTC 0.0304 0.7896 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 15:15:03 UTC 0.0304 0.7896 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 14:45:03 UTC -0.0013 0.8213 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 14:15:03 UTC -0.0013 0.8213 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 13:45:03 UTC -0.0013 0.8213 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 13:15:03 UTC -0.0013 0.8213 650000
MARINUS PHARMACEUTICALS INC MRNS 2022-05-17 12:45:03 UTC -0.0013 0.8213 650000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund MRNS -1779.0 shares, $-2739.66 2019-09-30 N-PORT
Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund MRNS -1400.0 shares, $-15932.0 2021-09-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund MRNS -375.0 shares, $-4455.0 2021-12-31 N-PORT

Elevate your investments